1/33
Looks like no tags are added yet.
Platelets: Structure
Small anucleated cells
Disc-shaped
Contain:
Microtubules
Actin cytoskeleton
Granules
Organelles
RNA
Platelets: Granules
Alpha: Store vWF, fibrinogen, growth factors
Dense: Contain ATP, Ca2+, serotonin
Platelets: Organelles
Lysosomes
Mitochondria
Peroxisomes
Platelets: RNA
Protein synthesis


Platelets: Function
Primary hemostasis
Vascular injury expose subendothelial collagen = Bind circulating vWF
Platelets bind circulating vWF, ADP, thrombin = Activation = Actin skeleton reorganization = Shape change
Disc → Sphere + Pseudopodia
Platelet degranulation + increase platelet aggregation and fibrinogen binding

Thrombopoiesis
In bone marrow
HSCs differentiate into CMP
CMP differentiate into megakaryoblasts
Megakaryoblasts → Megakaryocytes
Cytoplasm form long proplatelet extensions → Break off into platelets
Platelets (thrombocytes)

Thrombopoiesis: Regulation
Thrombopoietin
Secreted by liver and kidneys
Stimulate megakaryocyte proliferation + maturation
Thrombopoiesis: Disorders
Quantitative: Abnormal platelet count
Defects in…
Production
Destruction
Sequestration
Qualitative: Abnormal platelet function
Normal platelet count
Defects in…
Adhesion
Activation
Aggregation
Secretion
Signal transduction
Thrombocytopenia: Description
Low platelet count
< 150 × 10^9/L
Mild: > 70 × 10^9/L
Moderate: 20-70 × 10^9/L
Severe: < 20 × 10^9/L
Thrombocytopenia: Epidemiology
Common in inpatient and ambulatory settings
Thrombocytopenia: Etiology
Genetic mutations
vWD type 2B
Drug-induced
Immune thrombocytopenia (ITP)
Thrombotic microangiopathy (TMA)
Disseminated intravascular coagulation (DIC)
Drug-Induced Thrombocytopenia: Etiology
Anti-drug antibodies destroy platelets
Heparin (HIT)
Antithrombotic agents (abciximab)
CCB (amlodipine)
Na+ channel blockers (carbamazepine)
Sulfa drugs
ITP: Etiology
Produce anti-platelet antibodies
Ex: VITT (vaccine-induced immune thrombotic thrombocytopenia)
TMA: Etiology
Autoantibodies/gene mutations decrease ADAMTS13
ADAMTS13: Protein cleaving vWF
Normal: > 0.4 U/mL
Ex: Thrombotic thrombocytopenic purpura (TTP)
DIC: Etiology
Systemic clotting cascade activation
Thrombocytopenia: Pathogenesis
Decreased platelet production
Increased platelet destruction
Platelet sequestration
Thrombocytopenia Pathogenesis: Decreased Production
Caused by…
Congenital
Infections (CMV, EBV)
Malignancy
Decreased megakaryocyte precursors (megakaryoblasts, CMPs) = Decrease platelet production
Thrombocytopenia Pathogenesis: Increased Destruction
Drug-Induced:
Increased platelet-activating antibody production = Hypercoagulability = Decrease circulating platelets
ITP:
Stimulate anti-platelet antibody production = Bind platelets = Increase sequestration by spleen and liver = Decrease circulating platelets
TMA/TTP:
Decreased ADAMTS13 = Decrease vWF breakdown + Increase accumulation on endothelium
Increase platelet adhesion and microthrombi formation = Fragment RBC (schistocytes) = Hemolytic anemia
Decrease circulating platelets
DIC:
Increased procoagulants = Increased extrinsic coagulation cascade + platelet activation = Increase thrombin and fibrin
Increased platelet consumption = Low platelets
Microthrombi formation = Upregulate fibrinolysis + anticoagulant pathways
Increase anticoagulant consumption
Thrombocytopenia Pathogenesis: Platelet Sequestration
Liver disease and alcohol abuse
Liver dysfunction = Decrease thrombopoietin = Decrease megakaryoblast differentiation + platelet production
Portal hypertension = Splenomegaly
Splenomegaly
Large spleen = Increase sequestration = Destroy circulating platelets
Thrombocytopenia: Clinical Presentation
Mild: Asymptomatic
Moderate:
Increase bleeding after surgery/trauma
Easy bruising
Petechiae + purpura
Severe:
Ecchymoses, petechiae, purpura
Mucosal bleeding
Epistaxis
Jaundice
Hemolysis (RBC breakdown) = Increase bilirubin release
Intercranial hemorrhage → Neurological symptoms
Thrombocytopenia: Investigations
CBC
Coagulation studies
Liver chemistry
PBS
Renal function test
ELISA
Serotonin release assay
Thrombocytopenia: CBC
Low platelets
Compare to previous → Determine etiology
Thrombocytopenia: Coagulation Studies
PT, aPTT, INR
Increased bleeding time
Thrombocytopenia: Liver Chemistry
Increased bilirubin
Thrombocytopenia: PBS
Increased Destruction: Varying platelet sizes
TMA/TTP and DIC: Schistocytes
Decreased Production: Normal platelet size
Malignancy: Varying sizes + hypogranular
Thrombocytopenia: Renal Function Test
Serum creatinine, urea, uric acid, cystatin C
TMA/TTP: Renal dysfunction from AKI
Thrombocytopenia: ELISA
HIT: Anti-platelet factor 4 (PF4) or anti-heparin antibodies
VITT: Anti-PF4 antibodies
Positive → Serotonin release assay
Thrombocytopenia: Serotonin Release Assay
Increased serotonin from:
HIT: Patient serum + donor platelets + heparin
VITT: Patient serum + PF4 (no heparin)
Thrombocytopenia: Treatment/Management
Treat underlying cause
Review drugs
Plasma transfusion/exchange (PLEX)
*Thrombopoietin receptor agonist
**Corticosteroids + IVIG for ITP
Thrombocytopenia Management: Review Drugs
Stop drugs inhibiting platelets and coagulation cascade
Antiplatelet: NSAIDs, aspirin
Anticoagulant: DOACs
Thrombocytopenia Treatment: PLEX
Usually fresh frozen platelets (FFP)
Prophylactically:
ITP/VITT
During Severe Bleeding:
DIC
TMA/TTP
HIT
Thrombocytopenia Treatment: Thrombopoietin Receptor Agonist
Stimulate platelet production from megakaryocytes
For:
Liver disease
ITP
Thrombocytopenia: Complications
HIT: Heparin necrosis
Skin necrosis at heparin injection site
From: Microthrombi form around site = Cut off circulation = Necrotizing tissue
HIT, TMA/TTP, VITT: Thrombosis
Platelet activation increase clot formation
Organ dysfunction
Impaired wound healing
Ischemia = End-organ failure